Literature DB >> 29768997

Recent Advances on Glioblastoma Multiforme and Nano-drug Carriers: A Review.

Wang Liao1,2, Shengnuo Fan1, Yuqiu Zheng1, Shaowei Liao1, Ying Xiong1, Yi Li1, Jun Liu1,3,4.   

Abstract

Glioblastoma Multiforme (GBM) is the most frequent glioma with a poor prognosis. The mainstay treatment for GBM is chemotherapy, but the average survival of GBM remains unsatisfactory due to therapeutic resistance. Poor permeability restricted by the Blood Brain Barrier (BBB) and the presence of Glioblastoma Stem Cells (GSCs) remain as two problems for chemotherapy. Recently, nanocarriers have attracted much attention in the research of GBM, owing to their advantages in self-assembly, biosafety, release controllability, and BBB penetrability, making them promising candidates for GBM treatment. This article aims to review the biologic signatures of BBB and GSCs, as well as the new development of nano-drug delivery systems to facilitate our understanding of targeted treatment for GBM. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Glioblastoma multiforme; brain blood barrier; glioblastoma stem cells; gold; lipids; nanocarriers; targetedzzm321990therapy.

Mesh：

Substances：

Year:  2019        PMID： 29768997     DOI： 10.2174/0929867325666180514113136

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN： 0929-8673            Impact factor:   4.530


  6 in total

Review 1.  Glioblastoma: Current Status, Emerging Targets, and Recent Advances.

Authors:  Amandeep Thakur; Chetna Faujdar; Ram Sharma; Sachin Sharma; Basant Malik; Kunal Nepali; Jing Ping Liou
Journal:  J Med Chem       Date:  2022-07-05       Impact factor: 8.039

Review 2.  Drug Delivery Systems in the Development of Novel Strategies for Glioblastoma Treatment.

Authors:  Wiam El Kheir; Bernard Marcos; Nick Virgilio; Benoit Paquette; Nathalie Faucheux; Marc-Antoine Lauzon
Journal:  Pharmaceutics       Date:  2022-06-01       Impact factor: 6.525

3.  Nanoparticles of cisplatin augment drug accumulations and inhibit multidrug resistance transporters in human glioblastoma cells.

Authors:  Naseer Maliyakkal; Asmy Appadath Beeran; Nayanabhirama Udupa
Journal:  Saudi Pharm J       Date:  2021-07-15       Impact factor: 4.330

4.  Hyperbaric oxygen increases glioma cell sensitivity to antitumor treatment with a novel isothiourea derivative in vitro.

Authors:  Katarzyna Zembrzuska; Robert P Ostrowski; Ewa Matyja
Journal:  Oncol Rep       Date:  2019-03-14       Impact factor: 3.906

5.  Targeted Extracellular Vesicles Delivered Verrucarin A to Treat Glioblastoma.

Authors:  Kai Chen; Yingnan Si; Jia-Shiung Guan; Zhuoxin Zhou; Seulhee Kim; Taehyun Kim; Liang Shan; Christopher D Willey; Lufang Zhou; Xiaoguang Liu
Journal:  Biomedicines       Date:  2022-01-07

6.  A Comparison of Single- and Multiparametric MRI Models for Differentiation of Recurrent Glioblastoma from Treatment-Related Change.

Authors:  Felix Eisenhut; Tobias Engelhorn; Soheil Arinrad; Sebastian Brandner; Roland Coras; Florian Putz; Rainer Fietkau; Arnd Doerfler; Manuel A Schmidt
Journal:  Diagnostics (Basel)       Date:  2021-12-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.